Randomized phase III study of 5-FU [fluorouracil] continuous infusion (5-FUci) versus CPT-11 [irinotecan] plus CDDP (CP) [cisplatin] versus S-1 alone (S-1) in advanced gastric cancer (JCOG9912).

Trial Profile

Randomized phase III study of 5-FU [fluorouracil] continuous infusion (5-FUci) versus CPT-11 [irinotecan] plus CDDP (CP) [cisplatin] versus S-1 alone (S-1) in advanced gastric cancer (JCOG9912).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary) ; Cisplatin; Fluorouracil
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Dec 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Taiho Pharmaceutical Co., Ltd. and Yakult Honsha Co., LTD added as trial sponsors as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top